P/E ratio for Supernus Pharmaceuticals (SUPN)
P/E ratio as of May 2024 (TTM): 36.7
According to Supernus Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 36.6709. At the end of 2022 the company had a P/E ratio of 31.6.
P/E ratio history for Supernus Pharmaceuticals from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 31.6 | 10.42% |
| 2021 | 28.6 | 173.84% |
| 2020 | 10.4 | -5.37% |
| 2019 | 11.0 | -28.93% |
| 2018 | 15.5 | -55.98% |
| 2017 | 35.3 | 156.98% |
| 2016 | 13.7 | -70.39% |
| 2015 | 46.3 | -245.18% |
| 2014 | -31.9 | 1136.28% |
| 2013 | -2.58 | -24.59% |
| 2012 | -3.42 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.7 | -70.69% | 🇺🇸 USA |
 Abbott Laboratories ABT | 35.0 | -4.57% | 🇺🇸 USA |
 Eli Lilly LLY | 141 | 283.72% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -69.29% | 🇺🇸 USA |
 Zogenix ZGNX | -6.56 | -117.88% | 🇺🇸 USA |
 United Therapeutics UTHR | 14.0 | -61.92% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.